| Dr Jedidiah James Perkerewicz, MD | |
|
1245 Washington Ave, Detroit Lakes, MN 56501-3905 | |
| (218) 846-2000 | |
| Not Available |
| Full Name | Dr Jedidiah James Perkerewicz |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 17 Years |
| Location | 1245 Washington Ave, Detroit Lakes, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548469208 | NPI | - | NPPES |
| 16234 | Medicaid | ND |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207VX0000X | Obstetrics & Gynecology - Obstetrics | 11956 (North Dakota) | Secondary |
| 207V00000X | Obstetrics & Gynecology | 54222 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sanford Medical Center Fargo | Fargo, ND | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sanford Medical Center Fargo | 8426967803 | 1094 |
News Archive
Fox Chase Cancer Center researchers have identified a genetic marker that is associated with an earlier onset of prostate cancer in Caucasian men who have a family history of prostate cancer. If the data are confirmed, the marker may help clinicians personalize prostate cancer screening.
The Oslo-Axess-listed Norwegian biopharmaceutical company PCI Biotech Holding ASA today announced that it has raised NOK90 million through a new rights issue. The company received subscriptions for a total of approximately 3.36 million new shares. The initial offering was and remains 2,250,000 new shares, and the rights issue was thus oversubscribed by approximately 50 percent.
Emisphere Technologies, Inc. and Novo Nordisk A/S today announced that they have entered into an exclusive Development and License Agreement to develop and commercialize oral formulations of Novo Nordisk's insulins, which have the potential of treating diabetes, using Emisphere's Eligen® Technology. This is the second license agreement between the two companies. The first agreement, for the development of oral formulations of GLP-1 receptor agonists, was signed in June 2008, with a potential drug currently in a Phase I clinical trial.
The US National Institutes of Health (NIH) has awarded a $2.1 million "Grand Opportunity" (GO) grant to a team of researchers - led by Prof. Todd Lencz at the Feinstein Institute for Medical Research, New York, and Prof.Ariel Darvasi of the Silberman Institute of Life Sciences at the Hebrew University of Jerusalem - to conduct a study on the genetic basis of schizophrenia..
› Verified 3 days ago
| Entity Name | Sanford Clinic North |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942241351 PECOS PAC ID: 4284546151 Enrollment ID: O20031112000221 |
News Archive
Fox Chase Cancer Center researchers have identified a genetic marker that is associated with an earlier onset of prostate cancer in Caucasian men who have a family history of prostate cancer. If the data are confirmed, the marker may help clinicians personalize prostate cancer screening.
The Oslo-Axess-listed Norwegian biopharmaceutical company PCI Biotech Holding ASA today announced that it has raised NOK90 million through a new rights issue. The company received subscriptions for a total of approximately 3.36 million new shares. The initial offering was and remains 2,250,000 new shares, and the rights issue was thus oversubscribed by approximately 50 percent.
Emisphere Technologies, Inc. and Novo Nordisk A/S today announced that they have entered into an exclusive Development and License Agreement to develop and commercialize oral formulations of Novo Nordisk's insulins, which have the potential of treating diabetes, using Emisphere's Eligen® Technology. This is the second license agreement between the two companies. The first agreement, for the development of oral formulations of GLP-1 receptor agonists, was signed in June 2008, with a potential drug currently in a Phase I clinical trial.
The US National Institutes of Health (NIH) has awarded a $2.1 million "Grand Opportunity" (GO) grant to a team of researchers - led by Prof. Todd Lencz at the Feinstein Institute for Medical Research, New York, and Prof.Ariel Darvasi of the Silberman Institute of Life Sciences at the Hebrew University of Jerusalem - to conduct a study on the genetic basis of schizophrenia..
› Verified 3 days ago
| Entity Name | Sanford Medical Center Fargo |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184917924 PECOS PAC ID: 8426967803 Enrollment ID: O20110331000495 |
News Archive
Fox Chase Cancer Center researchers have identified a genetic marker that is associated with an earlier onset of prostate cancer in Caucasian men who have a family history of prostate cancer. If the data are confirmed, the marker may help clinicians personalize prostate cancer screening.
The Oslo-Axess-listed Norwegian biopharmaceutical company PCI Biotech Holding ASA today announced that it has raised NOK90 million through a new rights issue. The company received subscriptions for a total of approximately 3.36 million new shares. The initial offering was and remains 2,250,000 new shares, and the rights issue was thus oversubscribed by approximately 50 percent.
Emisphere Technologies, Inc. and Novo Nordisk A/S today announced that they have entered into an exclusive Development and License Agreement to develop and commercialize oral formulations of Novo Nordisk's insulins, which have the potential of treating diabetes, using Emisphere's Eligen® Technology. This is the second license agreement between the two companies. The first agreement, for the development of oral formulations of GLP-1 receptor agonists, was signed in June 2008, with a potential drug currently in a Phase I clinical trial.
The US National Institutes of Health (NIH) has awarded a $2.1 million "Grand Opportunity" (GO) grant to a team of researchers - led by Prof. Todd Lencz at the Feinstein Institute for Medical Research, New York, and Prof.Ariel Darvasi of the Silberman Institute of Life Sciences at the Hebrew University of Jerusalem - to conduct a study on the genetic basis of schizophrenia..
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jedidiah James Perkerewicz, MD 1245 Washington Ave, Detroit Lakes, MN 56501-3905 Ph: (218) 846-2000 | Dr Jedidiah James Perkerewicz, MD 1245 Washington Ave, Detroit Lakes, MN 56501-3905 Ph: (218) 846-2000 |
News Archive
Fox Chase Cancer Center researchers have identified a genetic marker that is associated with an earlier onset of prostate cancer in Caucasian men who have a family history of prostate cancer. If the data are confirmed, the marker may help clinicians personalize prostate cancer screening.
The Oslo-Axess-listed Norwegian biopharmaceutical company PCI Biotech Holding ASA today announced that it has raised NOK90 million through a new rights issue. The company received subscriptions for a total of approximately 3.36 million new shares. The initial offering was and remains 2,250,000 new shares, and the rights issue was thus oversubscribed by approximately 50 percent.
Emisphere Technologies, Inc. and Novo Nordisk A/S today announced that they have entered into an exclusive Development and License Agreement to develop and commercialize oral formulations of Novo Nordisk's insulins, which have the potential of treating diabetes, using Emisphere's Eligen® Technology. This is the second license agreement between the two companies. The first agreement, for the development of oral formulations of GLP-1 receptor agonists, was signed in June 2008, with a potential drug currently in a Phase I clinical trial.
The US National Institutes of Health (NIH) has awarded a $2.1 million "Grand Opportunity" (GO) grant to a team of researchers - led by Prof. Todd Lencz at the Feinstein Institute for Medical Research, New York, and Prof.Ariel Darvasi of the Silberman Institute of Life Sciences at the Hebrew University of Jerusalem - to conduct a study on the genetic basis of schizophrenia..
› Verified 3 days ago
Guillermo Alfredo Marroquin Galvez, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1027 Washington Ave, Detroit Lakes, MN 56501 Phone: 218-847-5611 | |
Dr. Bruce P Conmy, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1027 Washington Ave, Detroit Lakes, MN 56501 Phone: 218-847-5611 Fax: 218-847-0881 | |
James M Christensen, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1027 Washington Ave, Detroit Lakes, MN 56501 Phone: 218-847-5611 Fax: 218-847-0881 | |
Jaimie J. Deraney, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1245 Washington Ave, Detroit Lakes, MN 56501 Phone: 218-846-2000 Fax: 218-846-2114 | |
Julia Gabriela Vasquez Lopez, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1027 Washington Ave, Detroit Lakes, MN 56501 Phone: 218-847-5611 Fax: 218-844-2444 |